SCHEMBL9891497

SCHEMBL9891497

CC(C)(C)C1CCN1c1ccc(C(F)(F)F)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.48
CNR1 P21554 3/20 0.48
KDM4E B2RXH2 4/20 0.48
ABL1 P00519 1/20 0.48
LMNA P02545 1/20 0.48
GPR119 Q8TDV5 1/20 0.44
MAPT P10636 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
APAF1 O14727 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9891843 0.92 CNR2 (0.50) CNR2CNR1KDM4EABL1LMNA
SCHEMBL16253025 0.90 CNR2 (0.51) CNR2CNR1KDM4EABL1LMNA
SCHEMBL20458173 0.82 KDM4E (0.50) CNR2CNR1KDM4EABL1LMNA
SCHEMBL20458278 0.78 NR1H2 (0.56) CNR2CNR1KDM4EABL1LMNA
SCHEMBL14724222 0.78 CXCR3 (0.49) CNR2CNR1KDM4EABL1LMNA
SCHEMBL9891828 0.78 MAPT (0.43) CNR2CNR1KDM4EABL1LMNA
SCHEMBL9891883 0.78 MAPT (0.43) CNR2CNR1KDM4EABL1LMNA
SCHEMBL821334 0.77 KDM4E (0.61) KDM4EABL1LMNAGPR119MAPT
SCHEMBL16480380 0.77 CNR2 (0.49) CNR2CNR1KDM4EABL1LMNA
SCHEMBL20458193 0.76 CNR2 (0.62) CNR2CNR1KDM4EABL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 CNR2 1/4885CNR1 2/4885KDM4E 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.